Worth another lookWorth repeating. Lets get past the placebo BS. This is what we were looking for to go to Phase 3.
"substantial improvement in the primary endpoint absolute change in NIHSS
"Phase IIb clinical trial of NTx-265 in acute stroke showed that there was substantial improvement in the primary endpoint absolute change in NIHSS in both placebo treated patients and those receiving NTx-265 with no statistical differences between the groups."
I suspect Alan Moore will address this
Mediascan